Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

712
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
712
Dementia01:30

Dementia

204
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
204
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

278
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discriminating eclipse cues from weather.

Trends in plant science·2026
Same author

Observation of phase correlations in ferrofluids.

Scientific reports·2026
Same author

Spatial-Aware Transformer-GRU Framework for Enhanced Glaucoma Diagnosis From 3D OCT Imaging.

IEEE journal of biomedical and health informatics·2025
Same author

LAST-PAIN: Learning Adaptive Spike Thresholds for Low Back Pain Biosignals Classification.

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society·2025
Same author

Functionalizing the Electrical Properties of Kombucha Zoogleal Mats for Biosensing Applications.

ACS omega·2024
Same author

Living Plants Ecosystem Sensing: A Quantum Bridge between Thermodynamics and Bioelectricity.

Biomimetics (Basel, Switzerland)·2023

Related Experiment Video

Updated: Oct 1, 2025

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.0K

A Multi-Stream Convolutional Neural Network for Classification of Progressive MCI in Alzheimer's Disease Using

Mona Ashtari-Majlan, Abbas Seifi, Mohammad Mahdi Dehshibi

    IEEE Journal of Biomedical and Health Informatics
    |March 3, 2022
    PubMed
    Summary

    This study introduces a novel deep learning method for early Alzheimer's disease detection. The approach accurately distinguishes between stable and progressive mild cognitive impairment (MCI) using MRI data, improving diagnostic capabilities.

    More Related Videos

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    1.3K
    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
    05:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    392

    Related Experiment Videos

    Last Updated: Oct 1, 2025

    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
    08:43

    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

    Published on: August 7, 2017

    8.0K
    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
    09:47

    Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

    Published on: December 15, 2023

    1.3K
    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
    05:17

    Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

    Published on: April 18, 2025

    392

    Area of Science:

    • Neuroimaging
    • Artificial Intelligence
    • Neurology

    Background:

    • Early diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI) is crucial for timely intervention.
    • Distinguishing between stable MCI and progressive MCI is essential for predicting AD development.

    Purpose of the Study:

    • To develop and evaluate a multi-stream deep convolutional neural network (CNN) for classifying stable MCI and progressive MCI.
    • To leverage patch-based MRI data and anatomical landmarks for improved MCI classification.

    Main Methods:

    • Utilized a multi-stream deep CNN architecture fed with patch-based MRI data.
    • Identified distinct anatomical landmarks by comparing AD and cognitively normal MRI scans using multivariate statistical tests.
    • Employed a transfer learning approach, pre-training the model on AD and normal cognition data before fine-tuning on MCI data.

    Main Results:

    • The proposed method achieved an F1-score of 85.96% on the ADNI-1 dataset for MCI classification.
    • Outperformed existing methods in differentiating between stable and progressive MCI.
    • Demonstrated the effectiveness of patch-based MRI analysis and transfer learning in MCI diagnosis.

    Conclusions:

    • The developed multi-stream deep CNN shows significant promise for accurate and early detection of progressive MCI.
    • This AI-driven approach can aid clinicians in identifying individuals at higher risk of developing Alzheimer's disease.
    • The findings support the use of advanced neuroimaging analysis techniques for neurodegenerative disease diagnostics.